1 Holtgrave DR. Written Testimony on HIV/AIDS Incidence and Prevention For Hearing to be held September 16, 2008. http://www.apla.org/news-and-multimedia/news/public-statements/ayala_testimony_congressional_hearing.pdf. Accessed March 13, 2015.
2 The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. July 2010. https://www.hiv.gov/federal-response/national-hiv-aids-strategy/overview . Accessed March 9, 2017
5 Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. HIV-1-infected adults. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome. Abstract WELBC01.
6 Baeten J. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP study. HIV-1-infected adults. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011. Rome. Abstract MOAX0106.
8 CDC. HIV Surveillance Report, 2009; vol. 21. http://www.cdc.gov/hiv/pdf/statistics_2009_HIV_Surveillance_Report_vol_21.pdf. Accessed August 2, 2011.
10 Hall HI, Green TA, Wolitski RJ, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr 2010;55(2):271-6.
12 Purcell DW, Johnson C, Lansky A, et al. Estimate of number of MSM in the United States and MSM’s rates of HIV and syphilis. National STD Prevention Conference 2010. Atlanta, March 8-11, 2010. Abstract 22896.
17 Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
18 Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. May 24, 2010; pp 1-117. http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed August 2, 2011.
20 Fuller CM, Ford C, Rudolph A. Injection drug use and HIV: past and future considerations for HIV prevention and interventions. In: Mayer KH, Pizer HF, editors. HIV prevention: a comprehensive approach. London: Academic Press/Elsevier; 2009:305-339.
22 Hogben M, McNally T, McPheeters M, et al. The effectiveness of HIV partner counseling and referral services in increasing identification of HIV-positive individuals: a systematic review. Am J Prev Med 2007; 33(2 Suppl):S89-100.
24 Drumright LN, Colfax GN. HIV risk and prevention for non-injection substance users. In: Mayer KH, Pizer HF, editors. HIV prevention: a comprehensive approach. London: Academic Press/Elsevier; 2009:340-375.
25 Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: thecontribution of other sexually transmitted disease to sexual transmission of HIV infection. Sex Transm Infect 1999;75(1):3-17.
26 Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008;198(12):1804-8.
27 Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007;196(10):1500-8.
28 Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008;49(1):77-83.
- Page last reviewed: March 9, 2017
- Page last updated: March 9, 2017
- Content source: Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, Sexual Transmitted Diseases and Tuberculosis Prevention, Centers for Disease Control and Prevention